Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbial Transplants in Pancreatic Cancer
NCT04975217Phase 1Suspended
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fecal Microbiota Transplantation Capsule in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events. Started Dec 2021; status: suspended.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04975217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975217.